266 related articles for article (PubMed ID: 34405435)
21. Progressive multifocal leukoencephalopathy treated with nivolumab.
Hoang E; Bartlett NL; Goyal MS; Schmidt RE; Clifford DB
J Neurovirol; 2019 Apr; 25(2):284-287. PubMed ID: 30864100
[TBL] [Abstract][Full Text] [Related]
22. Progressive multifocal leukoencephalopathy: what's new?
Focosi D; Marco T; Kast RE; Maggi F; Ceccherini-Nelli L; Petrini M
Neuroscientist; 2010 Jun; 16(3):308-23. PubMed ID: 20479473
[TBL] [Abstract][Full Text] [Related]
23. Progressive multifocal leukoencephalopathy in Zambia is caused by JC virus with prototype regulatory region.
Mubanga E; Patel A; Siddiqi OK; Hanson BA; Dang X; Lakhi S; Mulundu G; Bender N; Koralnik IJ
J Neurovirol; 2019 Aug; 25(4):475-479. PubMed ID: 31028690
[TBL] [Abstract][Full Text] [Related]
24. Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes.
Steinhardt MJ; Wiercinska E; Pham M; Grigoleit GU; Mazzoni A; Da-Via M; Zhou X; Meckel K; Nickel K; Duell J; Krummenast FC; Kraus S; Hopkinson C; Weissbrich B; Müllges W; Stoll G; Kortüm KM; Einsele H; Bonig H; Rasche L
J Transl Med; 2020 Apr; 18(1):177. PubMed ID: 32316991
[TBL] [Abstract][Full Text] [Related]
25. Progressive multifocal leukoencephalopathy.
Weissert R
J Neuroimmunol; 2011 Feb; 231(1-2):73-7. PubMed ID: 20937530
[TBL] [Abstract][Full Text] [Related]
26. JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?
Diotti RA; Nakanishi A; Clementi N; Mancini N; Criscuolo E; Solforosi L; Clementi M
Clin Dev Immunol; 2013; 2013():967581. PubMed ID: 23878587
[TBL] [Abstract][Full Text] [Related]
27. Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: a new gold standard?
Roos-Weil D; Weiss N; Guihot A; Uzunov M; Bellanger A; Eymard B; Saadoun D; Houillier C; Idbaih A; Demeret S; Deback C; Leblond V; Galanaud D; Shor N; Pourcher V
J Neurol; 2021 Jul; 268(7):2458-2465. PubMed ID: 33515299
[TBL] [Abstract][Full Text] [Related]
28. The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era: Prevention and Management.
Molloy ES; Calabrese CM; Calabrese LH
Rheum Dis Clin North Am; 2017 Feb; 43(1):95-109. PubMed ID: 27890176
[TBL] [Abstract][Full Text] [Related]
29. Immunology of progressive multifocal leukoencephalopathy.
Jelcic I; Jelcic I; Faigle W; Sospedra M; Martin R
J Neurovirol; 2015 Dec; 21(6):614-22. PubMed ID: 25740538
[TBL] [Abstract][Full Text] [Related]
30. Successful cidofovir therapy of progressive multifocal leukoencephalopathy preceding angioimmunoblastic T-cell lymphoma.
Viallard JF; Lazaro E; Lafon ME; Pellegrin JL
Leuk Lymphoma; 2005 Nov; 46(11):1659-62. PubMed ID: 16334909
[TBL] [Abstract][Full Text] [Related]
31. Advances in the management of PML: focus on natalizumab.
Fox R
Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S33-7. PubMed ID: 22123933
[TBL] [Abstract][Full Text] [Related]
32. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
33. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
Perkins MR; Ryschkewitsch C; Liebner JC; Monaco MC; Himelfarb D; Ireland S; Roque A; Edward HL; Jensen PN; Remington G; Abraham T; Abraham J; Greenberg B; Kaufman C; LaGanke C; Monson NL; Xu X; Frohman E; Major EO; Douek DC
PLoS Pathog; 2012; 8(11):e1003014. PubMed ID: 23144619
[TBL] [Abstract][Full Text] [Related]
34. Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome.
Gheuens S; Bord E; Kesari S; Simpson DM; Gandhi RT; Clifford DB; Berger JR; Ngo L; Koralnik IJ
J Virol; 2011 Jul; 85(14):7256-63. PubMed ID: 21543472
[TBL] [Abstract][Full Text] [Related]
35. Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy.
Gasnault J; Costagliola D; Hendel-Chavez H; Dulioust A; Pakianather S; Mazet AA; de Goer de Herve MG; Lancar R; Lascaux AS; Porte L; Delfraissy JF; Taoufik Y;
PLoS One; 2011; 6(6):e20967. PubMed ID: 21738597
[TBL] [Abstract][Full Text] [Related]
36. [Progressive multifocal leukoencephalopathy--epidemiology, clinical pictures, diagnosis and therapy].
Kishida S
Brain Nerve; 2007 Feb; 59(2):125-37. PubMed ID: 17380777
[TBL] [Abstract][Full Text] [Related]
37. HIV-associated progressive multifocal leukoencephalopathy: longitudinal study of JC virus non-coding control region rearrangements and host immunity.
Iannetta M; Bellizzi A; Lo Menzo S; Anzivino E; D'Abramo A; Oliva A; D'Agostino C; d'Ettorre G; Pietropaolo V; Vullo V; Ciardi MR
J Neurovirol; 2013 Jun; 19(3):274-9. PubMed ID: 23715894
[TBL] [Abstract][Full Text] [Related]
38. [Progressive multifocal leukoencephalopathy and rheumatic disease].
Kneitz C; Wiendl H
Z Rheumatol; 2008 Jul; 67(4):290, 292-4. PubMed ID: 18483740
[TBL] [Abstract][Full Text] [Related]
39. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.
Tan CS; Koralnik IJ
Lancet Neurol; 2010 Apr; 9(4):425-37. PubMed ID: 20298966
[TBL] [Abstract][Full Text] [Related]
40. Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy.
Gasnault J; Kahraman M; de Goër de Herve MG; Durali D; Delfraissy JF; Taoufik Y
AIDS; 2003 Jul; 17(10):1443-9. PubMed ID: 12824781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
